Brean Capital’s healthcare analyst Difei Yang came out with a commentary on Zogenix, Inc. (NASDAQ:ZGNX), after the company announced positive top-line results in the Phase …
Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced positive top-line pharmacokinetic results from …
Brean Capital’s healthcare analyst Difei Yang weighed in today with a favorable report on Zogenix, Inc. (NASDAQ:ZGNX), after a study by scientists at UCSF was recently published …
Brean Capital’s healthcare analyst Difei Yang weighed in with a few insights on Zogenix, Inc. (NASDAQ:ZGNX), after the company released its second-quarter results, posting revenue of $7.
In a research report released Tuesday, William Blair analyst Tim Lugo reiterated a Market Perform rating on shares of Zogenix, Inc. (NASDAQ:ZGNX), after the company released …
Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, provided a corporate update, and …
Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing and commercializing unique therapies for the treatment of central nervous system (CNS) disorders, announced today the closing …
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing unique therapies for the treatment of central nervous system (CNS) disorders, announced today that it …
Gilead Sciences, Inc. (NASDAQ:GILD) shares spiked more than 4% in pre-market after the biopharmaceutical company beat estimates in its quarterly earnings.
Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing and commercializing unique therapies for the treatment of central nervous system (CNS) disorders, announced today that it …
